Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086840
Status:
TERMINATED
Last Update Posted:
2013-01-24
First Post:
2004-07-08
Brief Title:
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Study of CCI-779 in Patients With Relapsed Refractory or Transformed Chronic Lymphocytic Leukemia
Status:
TERMINATED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Administratively complete
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well CCI-779 works in treating patients with relapsed or refractory chronic lymphocytic leukemia Drugs used in chemotherapy such as CCI-779 work in different ways to stop cancer cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the activity of CCI-779 in patients with relapsed refractory or transformed chronic lymphocytic leukemia
OUTLINE Patients are stratified according to disease relapsed or refractory chronic lymphocytic leukemia CLL vs transformed CLL
Patients receive CCI-779 IV over 30 minutes on days 1 8 15 and 22 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity Patients achieving an objective response may receive 3 consolidation courses of therapy
I Determine the activity of CCI-779 in patients with relapsed refractory or transformed chronic lymphocytic leukemia
OUTLINE Patients are stratified according to disease relapsed or refractory chronic lymphocytic leukemia CLL vs transformed CLL
Patients receive CCI-779 IV over 30 minutes on days 1 8 15 and 22 Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity Patients achieving an objective response may receive 3 consolidation courses of therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000371619 | REGISTRY | PDQ Physician Data Query | httpsreporternihgovquickSearchN01CM17003 |
| MDA-2003-0886 | None | None | None |
| N01CM17003 | NIH | None | None |